Navigation Links
Interleukin Genetics to Present at G-2 Reports' Molecular Diagnostic Conference
Date:2/2/2009

CEO Lewis Bender Shares Vision for Genetic Testing Industry

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that Chief Executive Officer Lewis H. Bender will speak at the Washington G-2 Reports' Business & Financial Strategies for Molecular Diagnostics conference, taking place February 2-4, 2009 in Fort Lauderdale, FL. The presentation is scheduled for Wednesday, February 4 at 8:30 a.m.

As part of his discussion, Mr. Bender will address the opportunities and challenges that exist within the genetic personalized health industry. The presentation will center on navigating genetic tests through consumer and physician channels from a regulatory, scientific and marketing standpoint, while providing a case study example to demonstrate their medical utility.

"The benefits of genetic testing across channels are significant," said Bender. "Not only can drug developers improve their probability of success in clinical trials by using genetic biomarkers to screen out non-responders, but consumers can use genetic tests to improve wellness by personalizing their diet, environment and lifestyle choices best suited for their genetic makeup."

Washington G-2 Reports' Molecular Diagnostics conference will provide expert insight and advice on how laboratories can and are successfully integrating molecular diagnostics into their business strategies, given the current regulatory business environment.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE: Alternext US: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
2. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
3. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
4. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
5. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
6. Interleukin-12 indicates survival prospects for melanoma patients
7. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
8. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
9. T cell immunity enhanced by timing of interleukin-7 therapy
10. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
11. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Series at Zuckerberg San Francisco General Hospital on April 5-7. The series is ... and create new habits. The workshops cover a broad range of topics, including ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, ... to offer real-time business intelligence (BI) to their small and medium business (SMB) ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or loses ... Penn Burn Center, part of the Allegheny Health Network, has partnered with Etna ... “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance ... drive that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s ... “My school is in a low-income area and has more than 60 2nd and ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... Texas , Feb. 12, 2016 On ... for Robotic Surgery at St. David,s North Austin Medical ... da Vinci ® Xi ® Surgical System ... 7000dV. Thiru Lakshman , M.D., colorectal ... a total proctocolectomy utilizing Integrated Table Motion technology, which ...
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
Breaking Medicine Technology: